Abdominoperineal Resection: Consideration and Limitations of Prostate Cancer Screening and Prostate Biopsy by Klaassen, Zachary et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Consideration and Limitations of Prostate
Cancer Screening and Prostate Biopsy
Zachary Klaassen, Ray S. King, Kelvin A. Moses,
Rabii Madi and Martha K. Terris
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52291
1. Introduction
Prostate cancer and colorectal malignancies are the most common cancers in men, contributing
to 15% and 9% of new cancer cases, respectively [1]. Furthermore, it is not uncommon to en‐
counter patients with synchronous or metachronous colorectal and prostate cancers [2-3]. Ab‐
dominoperineal resection (APR) is often performed for surgical treatment of rectal cancer in
addition to treatment of ulcerative colitis and familial polyposis coli. The technical aspects of
an APR include a combined perineal and abdominal approach to resecting the rectum and mes‐
orectum, in addition to the anus, perineal soft tissue and pelvic floor musculature [4].
The screening and treatment of patients with prostate cancer after an APR is challenging
and unique. Enblad et al. [5] found a relative risk of 2.2 for the diagnosis of a second pri‐
mary neoplasm in the prostate within 1 year after the diagnosis of rectal malignancy. After
APR for colorectal pathologic features, however, there is no rectum for access to the pros‐
tate. This precludes the use of digital rectal examination (DRE) or transrectal ultrasound
(TRUS)-guided prostate biopsies to diagnose primary tumors of the prostate [6-10].
Several methods have been described to evaluate the prostate in the patient with elevated
prostate-specific antigen (PSA) levels who have undergone APR, including transperineal ul‐
trasound (TPUS)-guided biopsy, transurethral ultrasounded guided perineal biopsy and
computed tomography (CT)/magnetic resonance imaging (MRI) guided techniques. The aim
of this chapter is to review the screening for prostate cancer in patients preparing for an
APR and discuss post-APR screening and prostate biopsy techniques, limitations and practi‐
cal considerations.
© 2013 Klaassen et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Abdominoperineal resection
Abdominoperineal resection is a surgery for carcinoma of the rectum and/or anus, performed
through incisions in the abdomen and perineum. APR involves the removal of the anus, rec‐
tum, and the distal portion of the sigmoid colon along with regional lymph nodes. Without an
anal opening, the patient has a permanent end-colostomy from the proximal sigmoid colon cre‐
ated through the anterior abdominal wall, typically placed in the left lower quadrant [11-12].
2.1. Diagnosis of rectal carcinoma
In patients with rectal cancer, the most common initial presenting symptom or complaint is
bleeding, followed by changes in bowel habits, diarrhea, and lower abdominal pain. A DRE
may detect rectal masses located within the distal 1/3 of the rectum. A potential source of
confusion from a standard DRE may arise from carcinoma of the prostate encroaching on
the nearby rectum, causing similar obstructive symptoms [11]. Flexible sigmoidoscopy or
colonoscopy allow for a more thorough visual characterization, location, and size of the
mass, and provides an opportunity for biopsy and histological examination. Endoluminal
ultrasonography has recently been shown to be a diagnostic tool for characterizing the
depth of invasion of the rectal mass. Pre-operative evaluation using colonoscopy and CT
and/or MRI is indicated to rule-out synchronous lesions and/or metastatic disease [13].
2.2. Indications for treatment
Classic surgical dogma throughout the 20th century states that the standard treatment for
rectal tumors located less than 8cm from the anal verge is to perform an APR. Careful surgi‐
cal technique must be utilized to avoid complications such as recurrence of disease due to
inadequate surgical margins, anastomotic breakdown, obstruction, and re-operation. Tu‐
mors located more proximally are generally treated successfully using the standard low an‐
terior resection with restoration of bowel continuity. Absolute contraindications for
anastomosis following resection of rectal cancer are invasion of the sphincter mechanism or
the anal canal. The decision to preserve the anal sphincter can be affected by several factors
including: level of the tumor, depth of invasion, extent of circumferential involvement, tu‐
mor fixation, local and metastatic invasion, age, and the ability to manage a colostomy.
However, advances in instrumentation and techniques often allow for some tumors in the
distal rectum to be resected and anastomosis performed [13-14].
2.3. Technique
APR can be performed by a single surgeon or with a two-surgeon (abdominal and perineal)
team approach. Once the patient is prepped and draped, the anus is closed using a purse-
string suture. A site for the colostomy should be selected prior to incision. The surgeon may
consider preoperative ureteral stent placement to aid in identification of the ureters and to fa‐
cilitate repair in case of inadvertent injury. A midline infra-umbilical incision is made, and the
abdomen is explored for evidence of metastatic and/or synchronous disease. Once the tumor
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is deemed resectable, the surgeon on the perineal side can begin dissection simultaneously. In
the abdominal compartment, the sigmoid colon and rectum is mobilized by incision of the left
lateral mesentery, paying careful attention to avoid the left ureter as it courses over the bifur‐
cation of the iliac vessels. Identification and control of the inferior mesenteric artery is fol‐
lowed by its ligation distal to the first branch to maintain adequate blood supply to the colon
segment used for the stoma. The rectum is then bluntly dissected posterior along the presac‐
ral space and mobilized to the tip of the coccyx. Anteriorly, the rectum is retracted away from
the bladder and Denonvillier's fascia is incised to free the rectum away from the prostate to its
posterior margin. The lateral ligaments that contain the middle rectal arteries are controlled
and ligated. At this point the proximal sigmoid colon is divided using a stapling device and
brought through the anterior abdominal wall. The colostomy is then matured.
On the perineal side, an elliptical incision is made around the anus. Dissection is then made
through the sphincters and the ischiorectal fossa is entered. The presacral space is entered
from below and the rectum is mobilized circumferentially. Careful dissection is performed
to avoid perforation of the rectum and compromise the containment of the malignancy. The
perineal dissection is completed by dividing the levator muscle on each side. The distal sig‐
moid and rectum can be delivered through the perineal opening. The perineal wound is
closed primarily, with a closed drain left in place. The peritoneum is repaired above and the
floor of the pelvis is closed [12, 14-16].
3. Concomitant prostate cancer screening in the patient preparing for an
APR
Patients scheduled to undergo APR represent a patient population in which prostate cancer
screening may be indicated. Most cases of rectal cancer are diagnosed after 50 years of age
[17], and are in the same age category of men at risk for prostate cancer diagnosis. However,
the stage of rectal cancer should be taken into consideration when considering screening the
same individual for prostate cancer: Stage T1 and T2 rectal tumors treated with APR have a
~90% 5-year survival, while stage T3 and T4 tumors are generally treated with neoadjuvant
chemotherapy and/or radiation and generally have a 5-year survival of 50% and 25%, re‐
spectively [17]. Thus, prostate cancer screening in patients with advanced disease should be
avoided.
Terris and Wren previously described a prostate cancer-screening program for 19 consecu‐
tive men scheduled for APR for colorectal carcinoma with no history of prostate cancer [18].
Screening included serum PSA and DRE and those with suspicious findings underwent
TRUS-guided sextant biopsy. Six patients (31%) had a PSA >4.0 ng/mL (range 4.4 to 32.4
ng/mL, mean 9.3 ng/mL) of which two patients also had an abnormal DRE. TRUS-guided
biopsy revealed prostate cancer in three individuals (50%). These patients included an indi‐
vidual with clinical stage T1c, Gleason 3+3=6 adenocarcinoma of the prostate treated with
radiation, a second patient with clinical stage T2a, Gleason 3+4=7 adenocarcinoma of the
prostate treated with radiation, and a third individual with a PSA of 32.4 ng/mL and DRE
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consistent with extracapsular extension of prostate cancer (clinical stage T3, Gleason 4+4=8
adenocarcinoma of the prostate) managed with androgen deprivation therapy. Concomitant
prostate cancer screening for patients planning an APR should be a multi-disciplinary deci‐
sion between the General Surgeons and Urologist in the male patient older than 50 years of
age with clinical stage T1 or T2 rectal cancer and a life expectancy of more than 10 years.
4. Post-APR prostate cancer screening and modalities for prostate biopsy
The clinical scenario of a patient with an elevated PSA and no access to the rectum pre‐
cludes the urologist from performing a DRE or a TRUS biopsy of the prostate. Other ap‐
proaches to the prostate to allow a biopsy include CT and MRI guided techniques,
transurethral ultrasound guided perineal biopsy and TPUS-guided biopsy.
4.1. CT and MRI-guided prostate biopsy
Transgluteal CT-guided prostate biopsy involves imaging the lower pelvis at 10-mm inter‐
vals and with a 10-mm slice thickness. The transgluteal approach allows sampling of both
sides of the midline at the base, midgland and apical levels. When one entry site is used, the
angle of the needle is projected to the contralateral side of the prostate; entry sites are chosen
3-4cm off the midline to avoid paraspinal ligaments and potential post-APR fibrosis around
the tip of the coccyx (Figure 1) [19].
Figure 1. CT-guided percutaneous transgluteal biopsy of the prostate. Two needles are inserted at different angles to
ensure adequate sampling of both sides of the prostate (Reprinted from American Journal of Roentgenology, Volume
166/Issue 6, Papanicolaou N, Eisenberg PJ, Silverman SG, McNicholas MM, Althausen AF. 1996, 1332-1334, with per‐
mission from The American Roentgen Ray Society).
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Papanicolaou et al. [19] described this technique in 10 patients with a mean age of 67 years
and mean PSA of 33.9 diagnosing prostate cancer in 6 patients (60%). While CT scan offers
limited anatomical detail of the prostate, it does allow visualization of the peripheral zones
to facilitate biopsy in patients without rectal access.
Limited experience with MRI-guided transperineal biopsy [20] and CT-MRI fusion to guide
radiotherapy [21] has been described but is not widely available.
4.2. Transurethral ultrasound guided perineal prostate biopsy
The  patient  undergoing  a  transperineal  biopsy  guided  by  transurethral  ultrasound  is
placed in the lithotomy position and a 26F resectoscope sheath is passed into the urethra.
Subsequently, a 5.5 MHx transurethral ultrasound probe is passed through the sheath for
visualization of the prostate.  The width and height of the prostate are measured on the
sagittal image and withdrawing the probe from the base to the apex of the prostate assess‐
es length [22].  The advantage of this modality is that direct prostate imaging allows for
precise guidance of transperineally placed biopsy needles. However, the major limitation
is that one is only able to view the prostate in the sagittal plane. Seaman et al. [22] utiliz‐
ed this technique to perform 7 biopsies in 5 patients with a history of APR and elevated
PSA (two patients  had repeat  biopsy secondary to  increasing PSA),  diagnosing prostate
cancer in three patients (60%).
4.3. Transperineal Ultrasound (TPUS) guided prostate biopsy
The TPUS guided prostate biopsy is performed in the lithotomy position. A Foley catheter
may be inserted to delineate the prostate anatomy and avoid the urethra with the biopsy
needle [23]. The scrotum is then retracted anteriorly and the perineum is prepared in a ster‐
ile fashion. Then 1% Lidocaine is applied to the perineum for anesthesia. The transrectal ul‐
trasound probe is adjusted to a frequency of 5-6 MHz and the prostate is visualized after
traversing the course of the urethral catheter. The 18-guage biopsy needle is then directed at
a 45-degree angle and biopsy specimens are obtained through the posterior aspect of the
prostate. The needle forms an acute angle with the long axis of the prostate apex is nearly
parallel with the long axis of the prostate base and mid-gland (Figure 2). Biopsy specimens
are then obtained from the medial and lateral aspect of the prostate apex, mid-gland and
base as is performed for TRUS biopsy. A “fan technique” for obtaining a six-core TPUS
guided biopsy has also been described (Figure 3) [24].
A number of studies have compared the efficacy of TPUS-guided biopsies compared to
TRUS-guided biopsies in patients with a rectum [8, 24]. Shinghal and Terris [8] prospective‐
ly identified 20 patients with prostate cancer diagnosed by TRUS-guided biopsies to evalu‐
ate the accuracy of TPUS prostate biopsies. Six TPUS-guided biopsies were obtained,
followed by sextant TRUS-guided biopsies prior to radical prostatectomy. Final pathology
demonstrated that all 20 patients had adenocarcinoma of the prostate. TPUS-guided biop‐
sies identified cancer in only 2 of 20 patients (10%) compared to 13 of 20 patients (65%) for
TRUS-guided biopsies. The positive TPUS-guided biopsy specimens were higher Gleason
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grade, and were found in patients with larger volume prostates and higher PSA. Emiliozzi
et al. [24] performed a prospective study comparing TPUS versus TRUS-guided prostate bi‐
opsy in 107 patients with PSA > 4.0 ng/mL. The patients underwent TPUS-guided six core
biopsy, followed by TRUS-guided six core biopsy. Prostate cancer was found in 43 of 107
patients (40%): 41 (95%) were found via the TPUS approach compared to 34 (79%) via the
TRUS approach (p = 0.012).
Figure 2. Transperineal prostate biopsy. There is a relatively acute angle of the needle in regard to the long axis of the
prostate. The needle becomes almost parallel with the long axis of the prostate middle and base (Reprinted from The
Journal of Urology, Volume 169/Issue 1, Shinohara K, Gulati M, Koppie TM, Terris MK. 2003, 141-144, with permission
from American Urological Association).
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Figure 3. Scheme of the transperineal six-core fan biopsy. Cores are also taken from the far lateral aspect of the pros‐
tate (Reprinted from Urology, Volume 61/Issue 5, Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V.
2003, 961-966, with permission from Elsevier).
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A number of studies have reported TPUS-guided biopsy in patients after APR [6, 9, 23] (Ta‐
ble). Shinohara et al. [23] reported the largest experience analyzing 28 patients with a history
of APR who were referred for biopsy with a mean PSA of 22 ng/mL (median 9.5, range 4.1 to
237). The mean time from APR to referral was 14 years (range 1 to 33 years) and five patients
had previously undergone radiation therapy as part of the treatment for colorectal cancer.
Of the 28 patients, 23 were diagnosed with prostate cancer (82.1%), with a mean Gleason
score of 6.6 (range 3 to 9). Twenty-two of the 23 patients (95.7%) elected for treatment, in‐
cluding prostatectomy (n=8), androgen deprivation therapy (n=7), external radiation therapy













Shinohara et al. [23] 28 65 22 9.5 14 23 (82%)
Twidwell et al. [6] 10 67 NR NR 12 2 (20%)
Filderman et al. [99] 5 62 16.5 NR NR 2 (40%)
Table 1. A comparison of studies analyzing transperineal ultrasound-guided prostate biopsy results in patients after
abdominoperineal resection. (NR - not reported)
4.4. Practical considerations for TPUS-guided prostate biopsy
4.4.1. Image quality
The image quality of TPUS of the prostate compared to TRUS has been previously described
by Terris et al. [7]. In a prospective study of 50 patients who had not undergone APR, TPUS
was performed with a 4-MHz abdominal probe at a frequency of 5 - 7 MHz and TRUS at 7
MHz (Figure 4). TPUS allowed good visualization of the prostate in 48 (96%) patients in the
coronal plane and in 45 (90%) patients in the sagittal plane. Prostate volume, as calculated
by the prolate spheroid method, correlated well with TRUS calculations (r = 0.876). Prostatic
calcifications were seen in 12 patients (24%), identified by both TRUS and TPUS, however 29
patients (58%) with hypoechoic lesions identified by TRUS were not visualized by TPUS.
Furthermore, six patients (12%) with cystic lesions visualized by TRUS were seen in half of
the patients by TPUS (3/6). Image quality of TPUS is inadequate for staging purposes secon‐
dary to poor transverse and longitudinal visualization of the prostatic capsule. While the
imaging quality of TPUS may be inferior to TRUS, it likely represents the most reliable mo‐
dality in patients without access to the rectum and has been proposed as a diagnostic mo‐
dality in patients at high risk for prostate cancer with previous negative TRUS-guided
biopsies [25].
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Figure 4. A) Transperineal image showing vague outline of the prostate in the coronal plane. (B) Transverse image of
the prostate in the transverse plane. B = bladder; U = urethra (Reprinted from Urology, Volume 52/Issue 6, Terris MK,
Hammerer PG, Nickas ME. 1998, 1070-1072, with permission from Elsevier).
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4.4.2. Improved sampling of the far lateral peripheral zone
When performing TPUS-guided biopsy, the needle forms an acute angle with the long axis
of the prostate apex before becoming nearly parallel with the long axis of the prostate base
and mid-gland. Geometrically, this allows sampling of more peripheral zone tissue, notably
the far lateral peripheral zone [23, 25]. Eskew et al. [26] performed sextant biopsies in addi‐
tion to cores taken from the far lateral and mid regions of the prostate in 119 patients, diag‐
nosing prostate cancer in 48 patients (40.3%). Among these 48 patients, 17 (35%) had
carcinoma only in the far lateral and mid regions of the prostate.
5. Conclusions
Evaluation of the prostate in men with an elevated PSA who have undergone APR is chal‐
lenging due to inability to perform DRE and TRUS-guided prostate biopsy. TPUS-guided
prostate biopsy is the most cost effective and feasible modality for diagnosing prostate can‐
cer in these patients. However, given that men aged 50-75 are at increased risk for both pros‐
tate cancer and colorectal cancer, preoperative prostate cancer screening in men who are
planning APR allows for proper assessment of the prostate before access to the rectum is
compromised, provides a baseline PSA to compare with further testing after the APR, and
may detect synchronous malignancies. A multidisciplinary approach is ideal when consider‐
ing prostate cancer screening in men 50 years of age or older with reasonable life expectancy
who are planning APR.
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